In any case, the observation that patients with activated UPR (and presumably lower C/EBPα levels) display a more favorable outcome is consistent with the notion that C/EBPα mutations and inactivation are associated with a better prognosis in AML [105]. The gene discussed is CEBPA; the disease is acute myeloid leukemia.